

CITATION REPORT

List of articles citing

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study

DOI: 10.1016/j.eururo.2015.01.009
European Urology, 2015, 68, 207-13.

Source: <https://exaly.com/paper-pdf/62718773/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	Who and when should we screen for prostate cancer? Interviews with key opinion leaders. 2015 , 13, 288		8
104	Evaluation of individual aging degree by standard-free, label-free LC-MS/MS quantification of formaldehyde-modified peptides. 2015 , 140, 4137-42		
103	Prognosis: Proportionate response. 2015 , 528, S124-5		0
102	Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era. 2015 , 1, 149-151		
101	The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun. <i>European Urology</i> , 2015 , 68, 214-5	10.2	1
100	Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. 2016 , 17,		69
99	Molecular markers in urologic oncology: prostate cancer. 2016 , 26, 225-30		5
98	Biomarkers for prostate cancer: present challenges and future opportunities. 2016 , 2, FSO72		25
97	PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. 2016 , 1, 505-515		5
96	Another Reason to Consider Active Surveillance. <i>European Urology</i> , 2016 , 69, 582-583	10.2	0
95	A urologist's perspective on prostate cancer imaging: past, present, and future. 2016 , 41, 805-16		19
94	Prostate cancer markers: An update. 2016 , 4, 263-268		34
93	Prostate cancer biomarkers: Are we hitting the mark?. 2016 , 4, 130-135		58
92	Thoughts on Criteria for Active Surveillance of Favorable-risk Prostate Cancer. <i>European Urology</i> , 2016 , 70, 961-962	10.2	1
91	Risk stratification of prostate cancer 2016. 2016 , 245, S54-9		5
90	Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. 2016 , 26, 459-65		26
89	Successful external validation of a model to predict other cause mortality in localized prostate cancer. 2016 , 14, 25		15

88	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. 2016 , 34, 2705-11		48
87	Biomarkers in localized prostate cancer. 2016 , 12, 399-411		27
86	Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?. 2016 , 13, 140-2		19
85	The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. 2017 , 3, 94-99		9
84	Kallikreins Panel for Prostate Cancer Aggressiveness Prediction: More Is Not Enough. 2017 , 3, 100-101		
83	Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients. 2017 , 4, 315-321		3
82	Recent Advances in Clinical Research that Impact the Office Management of Prostate Cancer. 2017 , 4, 308-314		
81	A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer. 2017 , 15, 429-439.e1		45
80	Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. 2017 , 8, 14248		40
79	The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. <i>European Urology</i> , 2017 , 72, 942-949	10.2	20
78	The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. 2017 , 71, e12943		12
77	Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. 2017 , 27, 198-204		16
76	The role of prostate cancer biomarkers in undiagnosed men. 2017 , 27, 210-216		19
75	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017 , 72, 448-454	10.2	49
74	Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators. 2017 , 44, 517-524		13
73	Reply by Authors. 2017 , 198, 445-446		
72	Zinc as an Imaging Biomarker of Prostate Cancer. 2017 , 57, 854-861		11
71	Biomarkers in prostate cancer - Current clinical utility and future perspectives. 2017 , 120, 180-193		81

70	Current advances and future visions on bioelectronic immunosensing for prostate-specific antigen. 2017 , 98, 267-284	31
69	Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death. 2017 , 77, 41-48	14
68	Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. <i>European Urology</i> , 2018 , 73, 941-948	22
67	A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. 2018 , 199, 1459-1463	21
66	Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. 2018 , 56, 187-196	8
65	Molecular Biomarkers in the Clinical Management of Prostate Cancer. 2018 , 8,	10
64	Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. 2018 , 4, 790-803	41
63	Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. <i>European Urology</i> , 2018 , 73, 961-967	10.2 8
62	Role of Molecular Diagnostics in Prostate Cancer. 2018 , 151-177	2
61	Simulation in Surgery. 2018 , 439-488	
60	Prostate cancer screening-when to start and how to screen?. 2018 , 7, 34-45	6
59	Risk Assessment Based on Molecular and Genetic Markers in Prostate Cancer. 2018 , 1-16	
58	Novel Biomarkers for Prostate Cancer Detection and Prognosis. 2018 , 1095, 15-39	15
57	Molecular markers for prostate cancer. 2018 , 265-277	
56	Emerging biomarkers in the diagnosis of prostate cancer. 2018 , 11, 83-94	47
55	RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer. 2018 , 32, 234-244	29
54	Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. 2019 , 22, 84-90	11
53	Risk Assessment Based on Molecular and Genetic Markers in Prostate Cancer. 2019 , 109-124	

52	Biomarkers for Diagnosis and Prognosis of Prostate Cancer. 2019 ,	5
51	Obstacles in prostate cancer screening: Current issues and future solutions. 2019 , 12, 111-116	
50	A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. 2019 , 20,	57
49	Serum and urinary biomarkers for detection and active surveillance of prostate cancer. 2019 , 29, 593-597	8
48	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019 , 75, 399-407	10.2 23
47	Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. 2019 , 40, 246-253	17
46	A Four-kallikrein Panel and β Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. 2019 , 5, 561-567	7
45	Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men. 2020 , 80, 51-56	2
44	Identification and Validation of Leucine-rich β -glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. 2020 , 21, 51-60	6
43	The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer. 2020 , 16, 2421-2432	9
42	Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis. 2020 , 12,	8
41	Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers. 2020 , 2020, 8730608	10
40	The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population. 2020 , 29, 1381-1388	15
39	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. 2020 , 123, 604-609	3
38	Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer. 2020 , 112, 1013-1020	14
37	Serum and urine biomarkers for detecting clinically significant prostate cancer. 2021 , 39, 686-690	8
36	Early Diagnosis of Prostate Cancer from the Perspective of Chinese Physicians. 2020 , 11, 3264-3273	4
35	A discussion on controversies and ethical dilemmas in prostate cancer screening. 2020 ,	5

34	A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. 2021 , 148, 53-58	2
33	The GIBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. 2021 , 55, 116-124	4
32	Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer. 2021 , 42, 685-693	3
31	Diagnostic accuracy of [-2]proPSA versus Gleason score and Prostate Health Index versus Gleason score for the determination of aggressive prostate cancer: a systematic review. 2021 , 19, 1263-1291	
30	Association between one-time prostate-specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30-year prospective cohort study. 2021 , 128, 490-496	4
29	4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 10%: A meta-analysis. 2021 , 39, 366.e1-366.e10	
28	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. 2021 , 11,	3
27	Tumour markers of prostate cancer: The post-PSA era. 2021 , 45632211041890	1
26	Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. 2020 , 204, 281-288	8
25	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. 2016 , 11, e0155901	30
24	Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. 2017 , 19, 149-155	24
23	Differentiating Molecular Risk Assessments for Prostate Cancer. 2018 , 20, 12-18	6
22	How Precisely Can Prostate Cancer Be Managed?. 2016 , 20, S120-130	8
21	Optimal Use of PSA. 2017 , 257-267	
20	Prostate Cancer Tissue Diagnosis. 2018 , 457-473	
19	Simulation in Urology. 2019 , 289-317	
18	Current clinical utility of prostate cancer markers. 2019 , 13, 78-82	
17	Cancer/Testis Antigens Differentially Expressed in Prostate Cancer: Potential New Biomarkers and Targets for Immunotherapies.	

16	Risk factors of developing visceral metastases at diagnosis in prostate cancer patients.. 2019 , 8, 928-938	
15	The Clinical Applications of Serum and Urinary Biomarkers in Prostate Cancer. 2020 , 1, 30-38	
14	Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. 2015 , 17, 3-13	40
13	The 4Kscore Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. 2015 , 17, 231-40	27
12	Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system. 2017 , 19, 1-10	14
11	Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.. 2022 ,	1
10	Prostate cancer polygenic risk score and prediction of lethal prostate cancer.. 2022 , 6, 25	2
9	Machine learning algorithms to estimate 10-Year survival in patients with bone metastases due to prostate cancer: toward a disease-specific survival estimation tool.. 2022 , 22, 476	0
8	Value of PHI and PHID in the detection of intermediate- and high-risk prostate cancer.. 2022 , 531, 277-282	0
7	Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths. 2022 , 41, 81-87	
6	PSA: role in screening and monitoring patients with prostate cancer. 2022 , 131-172	
5	Association of Prostate-Specific Antigen Levels with Prostate Cancer Risk in a Multiethnic Population: Stability over Time and Comparison with Polygenic Risk Score.	0
4	Combined Use of Magnetic Resonance Imaging and Biomarker Testing to Detect Clinically Significant Prostate Cancer. 2023 , 50, 91-107	0
3	Molecular diagnosis of human oncogenic viruses associated with prostate cancer: Human Papillomavirus and Epstein-Barr virus. 2023 , 77-98	0
2	Relationship between ProclariX and the Aggressiveness of Prostate Cancer.	0
1	Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death Results from the Norwegian Prostate Cancer Consortium. 2023 ,	0